StockData
Alector, Inc. logo

Alector, Inc. (ALEC) company profile

ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$2.56−0.01 (-0.39%)

Close on Nov 17, 2026Market cap $285.84MP/E –Yield –

About Alector

Biological Products, (No Diagnostic Substances), SIC 2836

Alector, Inc. is a clinical-stage biotechnology company that discovers and develops therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The company utilizes its proprietary blood-brain barrier delivery technology, called Alector Brain Carrier, to transport antibodies, enzymes, and siRNA molecules into the central nervous system. Its clinical pipeline features nivisnebart, an investigational antibody undergoing clinical evaluation for early Alzheimer's disease in collaboration with GlaxoSmithKline. Preclinical candidates include an anti-amyloid beta antibody, an enzyme replacement therapy, and genetic therapies targeting tau, alpha-synuclein, and NLRP3. As a clinical-stage biopharmaceutical enterprise without commercialized therapies, its primary partners are pharmaceutical companies rather than commercial end customers.

The company maintains its principal executive offices and research laboratories in South San Francisco, California, along with additional facilities in Newark, California. Alector is incorporated under the laws of Delaware and manages international clinical trials across multiple regions, including the United States.

Summary of the business section of Alector's latest annual report, written by StockData.

Company profile

Company

Legal name
Alector, Inc.
Founded
2013
Headquarters
South San Francisco, CA
Address
131 Oyster Point Blvd., Suite 600 94080
Phone
(415) 231-5660
Employees
103, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
ALEC
Exchange
Nasdaq
IPO date
Feb 7, 2019
Shares outstanding
112M, Jul 31, 2026
Public float
$115.40M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
SEC CIK
1653087
CUSIP
014442107
ISIN
US0144421072
FIGI
BBG00N0PL198
Share class FIGI
BBG00N0PL214
LEI
549300Z8RQOIY1JMHC25
EIN
82-2933343

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Arnon RosenthalChief Executive Officer, Director3,514,600
Grace Wong-SaradPrincipal Accounting Officer161,570
Neil Lindsay BerkleyCFO & Chief Business Officer395,216
Sara Kenkare-MitraPresident and Head of R&D501,652
Marc GrassoChief Financial Officer296,072
Gary RomanoChief Medical Officer332,977
Elizabeth A. GarofaloDirector118,650
Mark AltmeyerDirector98,650
Errol B. DesouzaDirector98,650
Louis J. Lavigne JrDirector138,661
Richard H. SchellerDirector134,899
Kristine YaffeDirector124,109
Paula HammondDirector103,609

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.00M$1.86M$1.31M$17$135
FY2024$3.67M-$1.85M$1.93M$20$102
FY2023$4.26M$3.23M$1.98M$86$104
FY2022$3.52M-$7.80M$3.92M$54$111
FY2021$9.61M$15.24M$1.43M$120$125
FY2020$3.66M$4.88M$2.97M$88$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Arnon Rosenthal, Ph.D.
Co-founder, Chief Executive Officer
$678.10K–$422.88K$558.22K$325.49K$10.34K$2.00M-46%
Neil Berkley
Chief Financial Officer and Chief Business Officer
$455.00K$91.00K$128.14K$219.20K$152.88K$6.24K$1.05M-54%
Sara Kenkare-Mitra, Ph.D.
Former President and Head of Research and Development
$614.30K–$77.71K$17.81K$314.20K$551.13K$1.58M-38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 7, 2019
Offer price
$19.00
Securities offered
9,250,000
Gross proceeds
$175.75M
Exchange
Nasdaq
First trading day
Feb 7, 2019
First-day close
$18.00-5.3%
Lock-up ends (est.)
Aug 6, 2019

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 103 full-time employees, 70% of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 7, 2019IPOInitial public offering priced (424B4 prospectus)
Jan 31, 2019ListingRegistration of securities on an exchange (Form 8-A)
Sep 16, 2015Name changeName changed from Alector LLC to Alector, Inc.

See a number that looks wrong?